Frankfurt - Delayed Quote EUR

TME Pharma N.V. (0N6A.F)

Compare

0.0666

-0.0009

(-1.33%)

As of 3:29:01 PM GMT+1. Market Open.

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 0N6A.F

TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support

TME Pharma Provides Results of Fourth Exercise of Warrants Z

TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025

CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...

TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TME Pharma N.V. (0N6A.F)

Comparisons

Indicators

Technicals

Corporate Events

-4.03%

-2.77%

-46.46%

-51.03%

-3.06%

-67.67%

-99.85%

-99.97%

Recent News: 0N6A.F

TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support

TME Pharma Provides Results of Fourth Exercise of Warrants Z

TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025

CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...

TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025

TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting

TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update

TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma Provides Results of Third Exercise of Warrants Z

TME Pharma Announces Acceptance of the NCI’S Abstract on NOX-A12 in Glioblastoma for Presentation at the SNO 2024 Annual Meeting